Adult Asthmatics and Acid Reflux

• Status: Completed
• Trial end date: 2004-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess the efficacy and safety of Nexium in the treatment of subjects with persistent asthma believed to have acid reflux as a contributory factor to control of their asthma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Esomeprazole

Criteria

Inclusion Criteria:

• Clinical diagnosis of asthma

• Forced Expiratory Volume and Peak Expiratory Flow as defined by the protocol

• Daily use of inhaled GCS and/or leukotriene pathway modifier for greater than 3 months.

• Severe heartburn 3 days/week during the run-in period.

Exclusion Criteria:

• Subjects with a history of 3 sinus infections treated with antibiotics in the year prior to Visit 1.

• Any other significant disease or pathology judged to be clinically significant by the investigator